24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels

Coronary Artery Disease Clinical Trial

— DAPT-Lp(a)  

Official title:

24-Month Versus 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stent in Patients With Elevated Lipoprotein(a) Levels

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06014060
• Other study ID #: Lipoprotein(a) and prognosis
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2024
• Est. completion date: December 31, 2028

Study information

• Verified date: August 2023
• Source: China National Center for Cardiovascular Diseases
• Contact: Kefei Dou, MD, PhD
• Phone: +86-10-13801032912
• Email: drdoukefei[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is (1) to determine whether 24-month dual antiplatelet therapy (DAPT) is superior to 12-month DAPT after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) with respect to major adverse cardiovascular and cerebrovascular events (all-cause death, myocardial infarction, or stroke) in patients with elevated lipoprotein(a)[Lp(a)] levels (>30mg/dL); (2) to determine whether 24-month DAPT is non-inferior to 12-month DAPT after PCI with DES with respect to net adverse clinical events (all-cause death, myocardial infarction, stroke or Bleeding Academic Research Consortium [BARC] type 3 or 5 bleeding) in patients with elevated Lp(a) levels (>30mg/dL).

Description:

Lp(a) levels play an important role in predicting subsequent ischemic events in patients with established coronary artery disease (CAD), especially those who underwent PCI. However, there are still no approved pharmacologic therapies that specifically target high Lp(a) levels.

DAPT consisting of aspirin and a P2Y12 receptor inhibitor represents the cornerstone of pharmacological treatment aimed at preventing thrombotic complications after PCI. Considering that Lp(a) has a prothrombotic effect through its inactive, plasminogen-like protease domain on apo(a), the investigators speculate that prolonged DAPT may have a beneficial effect on reducing future ischemic events in patients with elevated Lp(a) levels after PCI. Some observational studies revealed that DAPT > 1 year was significantly associated with lower risk of cardiovascular events compared with DAPT ≤ 1 year in patients with elevated Lp(a) levels who were event-free at 1 year after PCI with DES. However, the relative efficacy and safety of prolonged DAPT versus standard DAPT in this high-risk population has never been assessed in randomized controlled trials (RCTs).

The DAPT-Lp(a) trial is a multicenter, parallel-group, randomized controlled trial with blinded end-point evaluation. Consecutive patients with Lp(a) levels>30mg/dL who meet the inclusion criteria and none of the exclusion criteria will be randomized in a 1:1 fashion to 24-month DAPT group or 12-month DAPT group. The investigators hypothesise that, in patients with Lp(a) levels >30mg/dL who were event-free at 1 year after PCI with DES, 24-month DAPT is superior to 12-month DAPT with respect to major adverse cardiovascular and cerebrovascular events (primary end point), while it is non-inferior to 12-month DAPT with respect to net adverse clinical events (key secondary end point).

The investigators estimated that 3,300 patients would be needed to provide the necessary number of confirmed endpoints to test the study hypothesis. Patients will be followed up at 3, 6, 9, 12 months after randomization. All analyses will be performed according to the intention-to-treat (ITT) principle.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 3300
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or nonpregnant female between 18-75 years;

2. Subjects with Lp(a) levels > 30mg/dL before percutaneous coronary intervention (PCI);

3. Subjects who are event-free at 1 year after PCI with drug-eluting stent (DES);

4. Subjects (or legal guardian) understand the trial requirements and the treatment procedures and provides written informed;

5. Subjects are willing to comply with all protocol-required follow-up evaluation.

Exclusion Criteria:

1. Subjects with Lp(a) < 30mg/dL or Lp(a) level unavailable before PCI;

2. Subjects who experience adverse cardiovascular events (death, myocardial infarction, stent thrombosis, stroke, repeat coronary revascularization, or Bleeding Academic Research Consortium [BARC] type 2, 3 or 5 bleeding) within 1-year after PCI;

3. Subjects who have other diseases requiring dual antiplatelet therapy (DAPT) such as peripheral vascular disease;

4. Subjects who cannot tolerate DAPT therapy or receive anticoagulation therapy at the time of randomization;

5. Planned surgery necessitating discontinuation of antiplatelet therapy (>14 days) within the 12 months after randomization;

6. Systolic blood pressure < 90mmHg for > 30 minutes accompanied by hypoperfusion symptoms or systolic blood pressure = 90mmHg is maintained with mechanical/pharmacologic hemodynamic support;

7. Unstable or severe pulmonary edema/decompensated congestive heart failure;

8. Moderate to severe heart failure (New York Heart Association [NYHA] Functional Classification III or IV) or last known left ventricular ejection fraction (LVEF) < 40%;

9. Severe valvular heart disease, myocarditis or cardiomyopathy;

10. Recurrent symptoms of ischemia;

11. Severe renal dysfunction, defined as creatinine clearance <30 mL/min or estimated glomerular filtration (eGFR) rate less than 30 ml/min/1.73m2, or requirement for peritoneal dialysis or hemodialysis for renal insufficiency;

12. History or clinical evidence of active liver disease or hepatic dysfunction, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN), or total bilirubin > 2 × ULN; Unexplained elevated creatine kinase (CK) concentration >5 × ULN or elevation due to known muscle disease;

13. Severe acute or chronic infectious disease;

14. History of severe rheumatic immune disease or malignant tumor;

15. Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(ies), or receiving other investigational agent(s);

16. Drug or alcohol abuse, and inability/unwillingness to abstain from drug abuse and excessive alcohol consumption during the study;

17. Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal);

18. Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the subject and investigator's knowledge;

19. Any uncontrolled or serious disease, or any medical or surgical condition (such as known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction, or a chronic disease or infection [eg, HIV]), that may either interfere with participation in the clinical study and is not currently stable and appropriately managed in the judgment of the investigator, and/or put the subject at significant risk (according to investigator's judgment) if he/she participates in the clinical study;

20. Mental/psychological impairment/neurocognitive disorder, or any other reason to expect patient difficulty in complying with the requirements of the study or understanding the goal and potential risks of participating in the study;

21. Concurrent medical condition with a life expectancy of < 1 year;

22. Subject unable to give informed consent;

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Drug-Eluting Stent
• Dual Antiplatelet Therapy
• Myocardial Ischemia

Intervention

Procedure:
• 24 Months DAPT
All subjects will receive co-administration of aspirin (100 mg/day) and clopidogrel (75 mg/day) for 12 months after randomization.
• 12 Months DAPT
All subjects will receive aspirin (100 mg/day) monotherapy without co-administration of clopidogrel for 12 months after randomization.

Locations

Country	Name	City	State
China	Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major adverse cardiovascular and cerebrovascular event (MACCE)	The primary endpoint was major adverse cardiovascular and cerebrovascular event (MACCE), defined as a composite of all-cause death, myocardial infarction or stroke.	12 months after randomization
Secondary	Net adverse clinical event (NACE)	The key secondary endpoint was net adverse clinical event, defined as a composite of all-cause death, myocardial infarction, stroke or Bleeding Academic Research Consortium (BARC)] type 3 or 5 bleeding.	12 months after randomization
Secondary	Cardiovascular death or myocardial infarction	Number of patients with a first occurrence of adjudicated composite of cardiovascular death or myocardial infarction.	12 months after randomization
Secondary	All-cause death or myocardial infarction	Number of patients with a first occurrence of adjudicated composite of all-cause death or myocardial infarction.	12 months after randomization
Secondary	All-cause death	Number of patients with the occurrence of adjudicated all-cause death.	12 months after randomization
Secondary	Cardiovascular death	Number of patients with the occurrence of adjudicated cardiovascular death.	12 months after randomization
Secondary	Any myocardial infarction	Number of patients with a first occurrence of adjudicated any myocardial infarction.	12 months after randomization
Secondary	Target vessel myocardial infarction	Number of patients with a first occurrence of adjudicated target vessel myocardial infarction.	12 months after randomization
Secondary	Stroke	Number of patients with a first occurrence of adjudicated stroke.	12 months after randomization
Secondary	Ischemic stroke	Number of patients with a first occurrence of adjudicated ischemic stroke.	12 months after randomization
Secondary	Hemorrhagic stroke	Number of patients with a first occurrence of adjudicated hemorrhagic stroke.	12 months after randomization
Secondary	Definite/probable stent thrombosis	Number of patients with a first occurrence of adjudicated definite/probable stent thrombosis.	12 months after randomization
Secondary	Repeat revascularization	Number of patients with a first occurrence of adjudicated repeat revascularization.	12 months after randomization
Secondary	Target vessel revascularization	Number of patients with a first occurrence of adjudicated target vessel revascularization.	12 months after randomization
Secondary	Any bleeding	Number of patients with a first occurrence of adjudicated any bleeding.	12 months after randomization
Secondary	BARC type 2, 3 or 5 bleeding	Number of patients with a first occurrence of adjudicated BARC type 2, 3 or 5 bleeding.	12 months after randomization
Secondary	BARC type 3 or 5 bleeding	Number of patients with a first occurrence of adjudicated BARC type 3 or 5 bleeding.	12 months after randomization